{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:53:22Z","timestamp":1794383602870,"version":"4.9.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Catastrophic antiphospholipid syndrome (CAPS) is a rare but life-threatening form of antiphospholipid syndrome (APS) defined by the rapid onset of large and small vessel thrombosis occurring simultaneously across multiple sites, resulting in multiorgan dysfunction. The presence of underlying immune dysfunction causing activation of coagulation and, in many cases, abnormal complement regulation predisposes these patients to thrombotic events. CAPS is often preceded by triggering factors such as infection, surgery, trauma, anticoagulation discontinuation, and malignancy. Given the high mortality rate, which may exceed 50%, prompt recognition and initiation of management is required. The detection of antiphospholipid antibodies and the histopathologic identification of microvascular ischemia via tissue biopsy are required to diagnose CAPS. However, these patients are often too unwell to obtain results and wait for them. As such, investigations should not delay CAPS therapy, especially if there is strong clinical suspicion. Management of CAPS requires \u201ctriple therapy\u201d with glucocorticoids, intravenous heparin, therapeutic plasma exchange, and\/or intravenous immunoglobulin. Treatment for refractory disease is based on poor-quality evidence but includes anti-CD20 (rituximab) or anticomplement (eculizumab) monoclonal antibodies and other immunosuppressant agents, either alone or in combination. The rarity of this syndrome and the subsequent lack of randomized clinical trials have led to a paucity of high-quality evidence to guide management. Continued international collaboration to expand ongoing CAPS registries will allow a better understanding of the response to newer targeted therapy.<\/jats:p>","DOI":"10.1182\/hematology.2024000544","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:02:25Z","timestamp":1733479345000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease"],"prefix":"10.1182","volume":"2024","author":[{"given":"Brittany M.","family":"Salter","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Andrew","family":"Crowther","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"3","key":"2024121115355504700_hem2024000544C1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-37-3-559","article-title":"Systemic lupus erythematosus preceded by false- positive serologic tests for syphilis: presentation of five cases","volume":"37","author":"Haserick","year":"1952","journal-title":"Ann Intern Med"},{"issue":"4","key":"2024121115355504700_hem2024000544C2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2024121115355504700_hem2024000544C3","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2024121115355504700_hem2024000544C4","doi-asserted-by":"crossref","first-page":"152265","DOI":"10.1016\/j.semarthrit.2023.152265","article-title":"Pulmonary involvement in catastrophic antiphospholipid syndrome: a descriptive analysis from the \u201cCAPS Registry.\u201d","volume":"63","author":"Ponce","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2024121115355504700_hem2024000544C5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11910-022-01228-0","article-title":"Neurologic manifestations of catastrophic antiphospholipid syndrome","volume":"22","author":"Mustafa","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"2024121115355504700_hem2024000544C6","doi-asserted-by":"crossref","first-page":"ytac199","DOI":"10.1093\/ehjcr\/ytac199","article-title":"Cardiovascular complications of catastrophic antiphospholipid syndrome: a case report and review of literature","volume":"6","author":"Mittal","year":"2022","journal-title":"Eur Heart J Case Rep"},{"issue":"2","key":"2024121115355504700_hem2024000544C7","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"issue":"12","key":"2024121115355504700_hem2024000544C8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th International Congress on Antiphospholipid Antibodies Task force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera","year":"2020","journal-title":"Lupus"},{"issue":"3-4","key":"2024121115355504700_hem2024000544C9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry","volume":"32","author":"Cervera","year":"2009","journal-title":"J Autoimmun"},{"issue":"6","key":"2024121115355504700_hem2024000544C10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/09537104.2020.1802414","article-title":"Catastrophic antiphospholipid syndrome refractory to high-dose intravenous immunoglobulin responsive to therapeutic plasma exchange","volume":"32","author":"James","year":"2021","journal-title":"Platelets"},{"issue":"7","key":"2024121115355504700_hem2024000544C11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"issue":"8","key":"2024121115355504700_hem2024000544C12","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2024121115355504700_hem2024000544C13","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2024121115355504700_hem2024000544C14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2024121115355504700_hem2024000544C15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2024121115355504700_hem2024000544C16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic antiphospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"Erkan","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2024121115355504700_hem2024000544C17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11926-007-0034-x","article-title":"Antiphospholipid antibodies in response to infection","volume":"9","author":"Avcin","year":"2007","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"2024121115355504700_hem2024000544C18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11420-008-9103-6","article-title":"Catastrophic antiphospholipid syndrome triggered by sepsis","volume":"5","author":"Kim","year":"2009","journal-title":"HSS J"},{"issue":"5","key":"2024121115355504700_hem2024000544C19","first-page":"541","article-title":"Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient \u201cseronegative\u201d antiphospholipid syndrome?","volume":"15","author":"Miret","year":"1997","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2024121115355504700_hem2024000544C20","first-page":"614","article-title":"Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus","volume":"16","author":"Drenkard","year":"1989","journal-title":"J Rheumatol"},{"issue":"11, pt 2","key":"2024121115355504700_hem2024000544C21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.lpm.2019.10.003","article-title":"Plasma exchange in catastrophic antiphospholipid syndrome","volume":"48","author":"Rodr\u00edguez-Pint\u00f3","year":"2019","journal-title":"Presse Med"},{"issue":"9","key":"2024121115355504700_hem2024000544C22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/medicina57090912","article-title":"Successful treatment of catastrophic antiphospholipid syndrome using rituximab: case report and review of the literature","volume":"57","author":"Stanescu","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"2024121115355504700_hem2024000544C23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2024121115355504700_hem2024000544C24","first-page":"355","article-title":"Rituximab treatment for resistant antiphospholipid syndrome","volume":"33","author":"Rubenstein","year":"2006","journal-title":"J Rheumatol"},{"issue":"9","key":"2024121115355504700_hem2024000544C25","first-page":"481","article-title":"Catastrophic antiphospholipid syndrome: a case series","volume":"15","author":"Shiber","year":"2013","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"2024121115355504700_hem2024000544C26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2024121115355504700_hem2024000544C27","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"21","key":"2024121115355504700_hem2024000544C28","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024121115355504700_hem2024000544C29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"2024121115355504700_hem2024000544C30","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024121115355504700_hem2024000544C31","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"issue":"4","key":"2024121115355504700_hem2024000544C32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2024121115355504700_hem2024000544C33","first-page":"744","article-title":"Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Ann Rheum Dis","volume":"81","author":"Kvacskay","year":"2022"},{"key":"2024121115355504700_hem2024000544C34","doi-asserted-by":"crossref","first-page":"667515","DOI":"10.3389\/fimmu.2021.667515","article-title":"Case report: resetting the humoral immune response by targeting plasma cells with daratumumab in antiphospholipid syndrome","volume":"12","author":"Pleguezuelo","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"2024121115355504700_hem2024000544C35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2019.02.006","article-title":"Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: maternal-fetal outcomes in a series of 18 cases","volume":"49","author":"Alijotas-Reig","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2024121115355504700_hem2024000544C36","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.42017","article-title":"Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis","volume":"74","author":"Ali","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2024121115355504700_hem2024000544C37","first-page":"2006","article-title":"Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator","volume":"29","author":"Burcoglu-O'Ral","year":"2002","journal-title":"J Rheumatol"},{"key":"2024121115355504700_hem2024000544C38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"2024121115355504700_hem2024000544C39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-med-042915-102529","article-title":"Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease","volume":"68","author":"Unlu","year":"2017","journal-title":"Annu Rev Med"},{"issue":"5","key":"2024121115355504700_hem2024000544C40","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/09612033221089138","article-title":"Refractory antiphospholipid antibody syndrome-induced thrombocytopaenia successfully treated with belimumab","volume":"31","author":"Yoshizuka","year":"2022","journal-title":"Lupus"},{"issue":"6","key":"2024121115355504700_hem2024000544C41","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/ard.2006.061671","article-title":"Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases","volume":"66","author":"G\u00f3mez-Puerta","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2024121115355504700_hem2024000544C42","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ket167","article-title":"Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases","volume":"52","author":"Hanouna","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2024121115355504700_hem2024000544C43","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/214\/2346605\/214salter.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/214\/2346605\/214salter.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T14:41:48Z","timestamp":1733928108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/214\/526202\/Catastrophic-antiphospholipid-syndrome-a-CAPS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000544","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}